Cellectis SA (CLLS) - Total Assets
Based on the latest financial reports, Cellectis SA (CLLS) holds total assets worth $289.19 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check total reinvestment intensity of Cellectis SA to assess the company's total reinvestment commitment from operating cash flow.
Cellectis SA - Total Assets Trend (2007–2025)
This chart illustrates how Cellectis SA's total assets have evolved over time, based on quarterly financial data. Explore CLLS long-term investment intensity to see how much of total assets are deployed in long-term investments.
Cellectis SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Cellectis SA's total assets of $289.19 Million consist of 72.8% current assets and 27.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.6% |
| Accounts Receivable | $22.20 Million | 6.8% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $535.00K | 0.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Cellectis SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CLLS stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cellectis SA's current assets represent 72.8% of total assets in 2025, a decrease from 79.3% in 2007.
- Cash Position: Cash and equivalents constituted 19.6% of total assets in 2025, down from 68.2% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 7.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 6.8% of total assets.
Cellectis SA Competitors by Total Assets
Key competitors of Cellectis SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Cellectis SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.52 | 1.67 | 5.45 |
| Quick Ratio | 1.52 | 1.67 | 5.40 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $70.05 Million | $109.26 Million | $228.91 Million |
Cellectis SA - Advanced Valuation Insights
This section examines the relationship between Cellectis SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.02 |
| Latest Market Cap to Assets Ratio | 0.69 |
| Asset Growth Rate (YoY) | -15.3% |
| Total Assets | $324.72 Million |
| Market Capitalization | $223.64 Million USD |
Valuation Analysis
Below Book Valuation: The market values Cellectis SA's assets below their book value (0.69x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Cellectis SA's assets decreased by 15.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Cellectis SA (2007–2025)
The table below shows the annual total assets of Cellectis SA from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $324.72 Million | -15.34% |
| 2024-12-31 | $383.54 Million | +14.74% |
| 2023-12-31 | $334.27 Million | +27.97% |
| 2022-12-31 | $261.22 Million | -31.63% |
| 2021-12-31 | $382.08 Million | -18.62% |
| 2020-12-31 | $469.47 Million | +0.43% |
| 2019-12-31 | $467.47 Million | -6.66% |
| 2018-12-31 | $500.84 Million | +50.46% |
| 2017-12-31 | $332.88 Million | +0.67% |
| 2016-12-31 | $330.68 Million | -11.32% |
| 2015-12-31 | $372.88 Million | +122.83% |
| 2014-12-31 | $167.34 Million | +279.34% |
| 2013-12-31 | $44.11 Million | -61.68% |
| 2012-12-31 | $115.11 Million | -12.72% |
| 2011-12-31 | $131.89 Million | +90.50% |
| 2010-12-31 | $69.23 Million | -24.20% |
| 2009-12-31 | $91.34 Million | +50.15% |
| 2008-12-31 | $60.83 Million | +12.92% |
| 2007-12-31 | $53.87 Million | -- |
About Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of las… Read more